Warning letter
Hobart Laboratories, Inc.: warning letter of Dec 6, 2002
FDA warning letter UCM145344 · Chicago District Office
Key facts
| Reference number | UCM145344 |
|---|---|
| Company | Hobart Laboratories, Inc. |
| Subject | CGMP in Manufacturing, Processing, Packing or Holding/CGMP for Finished Pharmaceuticals/Adulterated |
| Issue date | Dec 6, 2002 |
| Posted date | Dec 6, 2002 |
| Issuing office | Chicago District Office |
| Product type | Drugs |
| CFR sections cited | 211, 211.188, 211.142(a), 211.165(a), 211.165(d), 211.165(f) |
| Country | 3 |
| Inspection city | Bemidji |
| Inspection ZIP | 56601-9262 |
| Inspection start date | Sep 16, 2002 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: